Description
Pharmacological action
Pharmacotherapeutic group: Antiviral.
ATX code: J05AX13
Pharmacological properties of
Pharmacodynamics
Antiviral. Specifically inhibits influenza A and B viruses, the coronavirus associated with severe acute respiratory syndrome (SARS). According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect. It has interferon-inducing activity, It stimulates humoral and cellular immune responses, the phagocytic function of macrophages, and increases the body’s resistance to viral infections. It reduces the incidence of complications associated with a viral infection, as well as exacerbations of chronic bacterial diseases.
Therapeutic efficacy in viral infections is manifested in a decrease in the severity of general intoxication and clinical phenomena, a reduction in the duration of the disease, and a decrease in the risk of complications.
Refers to low-toxic drugs (LD50> 4 g / kg). It does not have any negative effects on the human body when administered orally in recommended doses.
Pharmacokinetics
Absorption – fast. It is quickly distributed to organs and tissues. The time to reach maximum concentration when taken at a dose of 50 mg is 1.2 hours, at a dose of 100 mg – 1.5 hours. Metabolized in the liver. The elimination half-life is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount by the kidneys (0.12%). During the first day, 90% of the administered dose is excreted.
Indications
Prevention and treatment in adults and children: influenza A and B, other acute respiratory viral infections.
Complex therapy of chronic bronchitis, pneumonia and recurrent herpetic infection.
Prevention of postoperative infectious complications.
Contraindications
Hypersensitivity to umifenovir or any component of the drug, lactose deficiency, lactose intolerance, glucose-galactose malabsorption, children under 3 years of age.
Composition Active substance: umifenovir hydrochloride monohydrate in terms of hydrochloride umifenovir –
0.0500 g Excipients: lactose monohydrate – 0.0861 g, povidone K-25 (polyvinylpyrrolidone medium molecular weight) – 0.0032 g, crospovidone – 0.0047 g, colloidal silicon dioxide (aerosil) – 0.0045 g, magnesium stearate – 0.0015 g.
Shell Excipients: Opadry II white [lactose monohydrate – 36%, hypromellose – 28%, titanium dioxide – 26%, macrogol-4000 (polyethylene glycol 4000) – 10%] – 0.0060 g
Dosage and Administration
Inside. Before eating.
Single dose (depending on age):
Age Single dose of the drug
From 3 to 6 years old 50 mg (1 tablet of 50 mg)
From 6 to 12 years old 100 mg (2 tablets of 50 mg or 1 tablet of 100 mg)
Older than 12 years old and adults 200 mg ( 4 tablets of 50 mg or 2 tablets of 100 mg)
Indication
regimen for children from 3 years of age and adults:
Non-specific prophylaxis during the period of the flu epidemic and other acute respiratory viral infections In a single dose 2 times a week for 3 weeks.
Non-specific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections In a single dose 1 time per day for 10-14 days.
Treatment of influenza and other acute respiratory viral infections in a single dose 4 times a day (every 6 hours) for 5 days.
Complex therapy of chronic bronchitis, pneumonia and recurrent herpes infection In a single dose 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
Prevention of postoperative infectious complications In a single dose 2 days before surgery, then 2 and 5 days after surgery.
Side effects
Rarely – allergic reaction.
Overdose
Not observed.
Storage conditions
At a temperature not exceeding 25C. Keep out of the reach of children.
Expiration
2 years.
Deystvuyuschee substances
Umyfenovyr
Conditions of release from drugstores
Without prescription
